STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

About Cellectis

Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.

Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs

Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.

Proprietary Technologies

Cellectis’s competitive edge lies in its proprietary technologies:

  • TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
  • PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.

These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.

Market Position and Industry Context

Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.

Competitive Landscape

Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.

Challenges and Opportunities

While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.

Conclusion

Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company, focuses on gene editing and cell therapies for cancer treatment. As of January 31, 2022, the total number of shares outstanding is 45,484,310, with 51,085,785 voting rights. The company aims to provide lifesaving UCART products targeting multiple cancers and has developed a new platform, .HEAL, for treating blood disorders. Cellectis strives to leverage its TALEN® technology and PulseAgile system for innovative therapies. It is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
Rhea-AI Summary

Cellectis has appointed Bing C. Wang, PhD, MBA, as the new Chief Financial Officer. Wang brings extensive experience in biotechnology finance, previously serving as CEO of Refuge Biotechnologies and in investment banking with Barclays and Citigroup. He will manage Cellectis’ global finance team, aiming to enhance the company’s financial strategy during its clinical trial developments. Wang's background includes strategic capital raising and corporate finance, making him a valuable addition to Cellectis as it focuses on developing off-the-shelf cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
management
-
Rhea-AI Summary

Cellectis announced its share and voting rights status as of December 31, 2021. The total number of shares in capital stood at 45,484,810, while the total number of voting rights reached 51,085,782. The company specializes in gene editing and is known for its innovative CAR-T immunotherapies aimed at treating various cancers, including acute myeloid leukemia and multiple myeloma. Cellectis operates from its headquarters in Paris and has a presence in New York and North Carolina. Its commitment to developing life-saving therapies positions it as a leader in the biotech sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Summary

Cellectis (Nasdaq: CLLS) reported that the FDA has lifted the clinical hold on its partner Allogene Therapeutics’ clinical trials, enabling the resumption of studies for ALLO-501A, an anti-CD19 CAR-T cell therapy. This decision follows investigations revealing that a chromosomal abnormality found in a single patient was unrelated to TALEN® gene editing or Allogene’s manufacturing process. The abnormality's clinical significance was deemed negligible.

Allogene plans to start a pivotal Phase 2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma by mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
-
Rhea-AI Summary

Cellectis (Nasdaq: CLLS) announced its 2022 business objectives, focusing on ongoing clinical trials BALLI-01, AMELI-01, and MELANI-01. The company aims to enroll patients in these trials and file an IND for UCART20x22, its first dual allogeneic CAR-T product. Cellectis has operational manufacturing sites in Raleigh and Paris, projecting its cash runway into early 2024 with $201 million available as of September 30, 2021. The company is committed to advancing its pipeline of life-saving cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
Rhea-AI Summary

Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, targeting relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study demonstrated that UCART22 can be administered safely after lymphodepletion with FCA, showing no dose-limiting toxicities. Encouraging anti-leukemic activity was observed in 2 out of 6 patients, with one achieving blast reduction to 0%. The trial is currently enrolling at dose level 3. Additionally, preclinical data for TALGlobin01 showed efficient correction of the mutated beta-globulin gene for sickle cell disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Cellectis, a gene editing company, reported its share and voting rights on November 30, 2021, with a total of 45,477,810 shares and 51,079,282 voting rights. The company focuses on CAR-T immunotherapies and gene editing technologies for cancer treatment. Headquartered in Paris, Cellectis is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The firm targets various cancers, utilizing its TALEN® technology and the PulseAgile system, aiming to address unmet medical needs. For more details, visit www.cellectis.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.53%
Tags
none
-
Rhea-AI Summary

Cytovia Therapeutics has expanded its collaboration with Cellectis to develop gene-edited NK and CAR-NK cells, enhancing cancer treatment options. The agreement includes $20 million in equity for Cytovia and up to $805 million in potential milestones. This strategic partnership also grants Cytovia exclusive rights to modify NK cells using TALEN® technology, facilitating advancement in various cancer indications, particularly in China through their joint venture, CytoLynx Therapeutics. The collaboration aims to leverage innovative immunotherapies targeting unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
partnership
-
Rhea-AI Summary

Cellectis S.A. (NASDAQ: CLLS) announced significant preclinical data for UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin for the treatment of solid tumors. The data presented at SITC's 36th Annual Meeting indicate that mesothelin is a promising target for CAR-T therapy due to its high expression in certain cancers. UCARTMESO demonstrated potent activity in vitro and in mouse models of pancreatic and pleural mesothelioma. The knockout of TGFBR2 genes enhances its effectiveness even in immunosuppressive tumor environments, suggesting a potential breakthrough in solid tumor treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
Rhea-AI Summary

Cellectis announced its share and voting rights update as of October 31, 2021. The total number of shares in circulation is 45,475,310, while the total number of voting rights stands at 51,076,779. As a gene editing company, Cellectis focuses on CAR-T therapies for oncology and has 21 years of expertise in the field. Its approach includes off-the-shelf gene-edited CAR T-cells and a new platform targeting hemopoietic stem cells for various diseases. Cellectis is listed on Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

The current stock price of Cellectis (CLLS) is $1.15 as of April 4, 2025.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately 131.1M.

What does Cellectis specialize in?

Cellectis specializes in developing gene-edited cancer immunotherapies, particularly allogeneic CAR-T cells, and other therapeutic applications using its proprietary TALEN® technology.

How does Cellectis differentiate from competitors?

Cellectis focuses on allogeneic CAR-T therapies, which offer scalability and cost advantages over autologous approaches. Its proprietary TALEN® technology ensures precise gene editing.

What are Cellectis’s proprietary technologies?

Cellectis utilizes TALEN® for precise gene editing and the PulseAgile electroporation system for efficient genetic material delivery into cells.

What challenges does Cellectis face?

As a clinical-stage company, Cellectis faces challenges such as regulatory hurdles, high R&D costs, and competition from other biotech firms in the gene-editing and immunotherapy space.

What is the significance of allogeneic CAR-T therapies?

Allogeneic CAR-T therapies use gene-edited donor cells, providing scalability, reduced manufacturing costs, and faster availability compared to patient-specific autologous therapies.

What market does Cellectis target?

Cellectis targets the immuno-oncology market with its cancer immunotherapies and explores other therapeutic indications through gene-edited hematopoietic stem and progenitor cells.

Who are Cellectis’s main competitors?

Competitors include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which focus on gene-editing technologies and related therapies.

What stage of development is Cellectis in?

Cellectis is a clinical-stage biopharmaceutical company, focusing on research, development, and clinical trials for its product candidates.
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

131.12M
69.31M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris